Fight against prostate cancer
Prostate cancer is the second most common cancer in Spanish men. More than 30.000 men are diagnosed with prostate cancer every year in Spain.
Total raised €100%raised
Ticketmaster clients 6.106€
Those people who have naturally benefited from the project's interventions.
Those identifiable people who will potentially recieve an effect from the project's activities.
- Materials 2.104€
- Staff 4.000€
- Total 6.104€
Only men have a prostate gland. The prostate is usually the size and shape of a walnut and grows bigger as you get older. It sits underneath the bladder and surrounds the urethra – the tube men urinate (pee) and ejaculate through.
Prostate cancer can develop when cells in the prostate start to grow in an uncontrolled way. Prostate cancer often grows slowly to start with and may never cause any problems. But some men have prostate cancer that is more likely to spread. This needs treatment to stop it spreading outside the prostate.
The study led by Dr. Anna María Margalef of the Research Institute of the Vall d'Hebron University Hospital (VHIR) consists of studying the possible prognostic value of KIF11 expression in prostate tumors with MYC amplified / overexpressed. In addition, they will explore the therapeutic value of KIF11 in preclinical models and models derived from patients that recapitulate the disease more faithfully (main objective of this proposal).
Increase life expectancy of those affected by prostate cancer.
- Develop new therapeutic treatments for prostate cancer.
- Validate KIF11 as an important therapeutic target for the treatment of hormone-refractory prostate tumors, especially those that present amplification or overexpression of the MYC oncogene.
Who will benefit?
Life expectancy of patients and future patients with prostate cancer will be increased.